Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koltun

Showing results (391-400 of 423) with videos related to

Pageof 43
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 30, 2026
HR-pQCT skeletal phenotype clustering associated with muscle function in older men and women: The Study of Muscle, Mobility and Aging (SOMMA)Morgan W Bolger, Kerri S Freeland, Megan M Marron, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2016
Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazineDmitry O Koltun, Eric Q Parkhill, Elfatih Elzein, et al.
International Journal of Molecular Sciences|November 26, 2022
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo ModelYiftah Barsheshet, Tali Voloshin, Boris Brant, et al.
Molecular Cancer Therapeutics|June 30, 2025
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug ResistanceBella Koltun, Tali Voloshin, Cfir David, et al.
Bioorganic & Medicinal Chemistry Letters|April 4, 2016
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazineDmitry O Koltun, Eric Q Parkhill, Elfatih Elzein, et al.
Physiological Reports|March 15, 2024
Skeletal muscle adaptations to high-intensity, low-volume concurrent resistance and interval training in recreationally active men and womenAdam J Sterczala, Nathaniel Rodriguez-Ortiz, Evan D Feigel, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailabilityElfatih Elzein, Prabha Ibrahim, Dmitry O Koltun, et al.
Antimicrobial Agents and Chemotherapy|May 21, 2014
Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas diseaseMaria T Bahia, Alvaro F S Nascimento, Ana Lia Mazzeti, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Discovery of a new class of glucosylceramide synthase inhibitorsElena Koltun, Steven Richards, Vicky Chan, et al.
Bone|July 11, 2026
Unsupervised machine learning derived bone phenotypes exhibit differential biomarker responses following acute ballistic loaded exerciseJenna B Goulart, Christopher K Kargl, Adam J Sterczala, et al.
Pageof 43

Showing results (391-400 of 423) with videos related to

Sort By:
Pageof 43
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 30, 2026
HR-pQCT skeletal phenotype clustering associated with muscle function in older men and women: The Study of Muscle, Mobility and Aging (SOMMA)Morgan W Bolger, Kerri S Freeland, Megan M Marron, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2016
Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazineDmitry O Koltun, Eric Q Parkhill, Elfatih Elzein, et al.
International Journal of Molecular Sciences|November 26, 2022
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo ModelYiftah Barsheshet, Tali Voloshin, Boris Brant, et al.
Molecular Cancer Therapeutics|June 30, 2025
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug ResistanceBella Koltun, Tali Voloshin, Cfir David, et al.
Bioorganic & Medicinal Chemistry Letters|April 4, 2016
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazineDmitry O Koltun, Eric Q Parkhill, Elfatih Elzein, et al.
Physiological Reports|March 15, 2024
Skeletal muscle adaptations to high-intensity, low-volume concurrent resistance and interval training in recreationally active men and womenAdam J Sterczala, Nathaniel Rodriguez-Ortiz, Evan D Feigel, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailabilityElfatih Elzein, Prabha Ibrahim, Dmitry O Koltun, et al.
Antimicrobial Agents and Chemotherapy|May 21, 2014
Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas diseaseMaria T Bahia, Alvaro F S Nascimento, Ana Lia Mazzeti, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Discovery of a new class of glucosylceramide synthase inhibitorsElena Koltun, Steven Richards, Vicky Chan, et al.
Bone|July 11, 2026
Unsupervised machine learning derived bone phenotypes exhibit differential biomarker responses following acute ballistic loaded exerciseJenna B Goulart, Christopher K Kargl, Adam J Sterczala, et al.
Pageof 43